By a News Reporter-Staff News Editor at Anti-Infectives Week -- Fresh data on Drugs and Therapies are presented in a new report. According to news reporting out of Beijing, People's Republic of China, by NewsRx editors, research stated, "Three tilmicosin-loaded hydrogenated castor oil nanoparticle (TMS-HCO-NP) suspensions of different particle sizes were prepared with different polyvinyl alcohol surfactant concentrations using a hot homogenization and ultrasonic technique. The in vitro release, in vitro antibacterial activity, mammalian cytotoxicity, acute toxicity in mice, and stability study were conducted to evaluate the characteristics of the suspensions."
Our news journalists obtained a quote from the research from China Agricultural University, "The in vitro tilmicosin release rate, antibacterial activity, mammalian cytotoxicity, acute toxicity in mice, and stability of the suspensions were evaluated. When prepared with polyvinyl alcohol concentrations of 0.2%, 1%, and 5%, the mean diameters of the nanoparticles in the three suspensions were 920+/-35 nm, 452+/-10 nm, and 151+/-4 nm, respectively. The three suspensions displayed biphasic release profiles similar to that of freeze-dried TMS-HCO-NP powders, with the exception of having a faster initial release. Moreover, suspensions of smaller-sized particles showed faster initial release, and lower minimum inhibitory concentrations and minimum bactericidal concentrations. Time-kill curves showed that within 12 hours, the suspension with the 151 nm particles had the most potent bactericidal activity, but later, the suspensions with larger-sized particles showed increased antibacterial activity. None of the three suspensions were cytotoxic at clinical dosage levels. At higher drug concentrations, all three suspensions showed similar concentration-dependent cytotoxicity. The suspension with the smallest-sized particle showed significantly more acute toxicity in mice, perhaps due to faster drug release. All three suspensions exhibited good stability at 4 degrees C and at room temperature for at least 6 months."
According to the news editors, the research concluded: "These results demonstrate that TMS-HCO-NP suspensions can be a promising formulation for tilmicosin, and that nanoparticle size can be an important consideration for formulation development."
For more information on this research see: Preparation and evaluation of tilmicosin-loaded hydrogenated castor oil nanoparticle suspensions of different particle sizes. International Journal of Nanomedicine, 2014;9():2655-2664. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Drugs and Therapies).
Our news journalists report that additional information may be obtained by contacting X.J. Chen, China Agricultural University, Coll Vet Med, Dept. of Vet Prevent Med, Beijing 100193, People's Republic of China. Additional authors for this research include T. Wang, M.M. Lu, L.Y. Zhu, Y. Wang and W.Z. Zhou.
Keywords for this news article include: Asia, Antibacterial, Antibiotics, Antimicrobials, Beijing, Drugs and Therapies, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC